Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership

finance.yahoo.com/news/eli-lilly-co-lly-expands-212806633.html

In This Article:
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will lead early-stage research, while Lilly handles clinical…

This story appeared on finance.yahoo.com, 2025-05-17 21:28:06.
The Entire Business World on a Single Page. Free to Use →